1652 related articles for article (PubMed ID: 26281148)
1. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
3. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
4. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
5. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
6. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
7. Beyond Criteria and Definitions: Outcome of a Standardized Antibody-Mediated Rejection Protocol with a Diagnostic Schema Different from the Banff 2009 Criteria.
Rendulic T; Ramon DS; Killen PD; Samaniego-Picota M; Park JM
Clin Transpl; 2014; ():179-87. PubMed ID: 26281143
[TBL] [Abstract][Full Text] [Related]
8. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
[TBL] [Abstract][Full Text] [Related]
10. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
11. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience.
Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M
Clin Transpl; 2011; ():373-9. PubMed ID: 22755434
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
13. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
14. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
15. Targeted monitoring of donor-specific HLA antibodies following renal transplantation.
Almeshari K; Pall A; Chaballout A; Elgamal H; Almana H; Alzayer F; Abaalkhail N; Altalhi M
Clin Transpl; 2011; ():395-400. PubMed ID: 22755437
[TBL] [Abstract][Full Text] [Related]
16. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
17. Desensitization in kidney transplantation: review and future perspectives.
Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
[TBL] [Abstract][Full Text] [Related]
18. Desensitization Before Living Donor Kidney Transplantation in Highly HLA-Sensitized Patients: A Single-Center Study.
De Sousa-Amorim E; Revuelta I; Blasco M; Diekmann F; Cid J; Lozano M; Sánchez-Escuredo A; Martorell J; Palou E; Campistol JM; Oppenheimer F
Transplant Proc; 2015 Oct; 47(8):2332-5. PubMed ID: 26518919
[TBL] [Abstract][Full Text] [Related]
19. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction.
Cooper JE; Gralla J; Klem P; Chan L; Wiseman AC
Transplantation; 2014 Jun; 97(12):1253-9. PubMed ID: 24937199
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
